CN105816813A - Medicine composition for treating breast cancer and preparing method and application of medicine composition - Google Patents
Medicine composition for treating breast cancer and preparing method and application of medicine composition Download PDFInfo
- Publication number
- CN105816813A CN105816813A CN201610286686.4A CN201610286686A CN105816813A CN 105816813 A CN105816813 A CN 105816813A CN 201610286686 A CN201610286686 A CN 201610286686A CN 105816813 A CN105816813 A CN 105816813A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- rhizoma
- pharmaceutical composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 59
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 59
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims description 32
- 229940079593 drug Drugs 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 title abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 69
- 238000011282 treatment Methods 0.000 claims abstract description 55
- 241000756943 Codonopsis Species 0.000 claims abstract description 33
- 239000002994 raw material Substances 0.000 claims abstract description 32
- 239000009636 Huang Qi Substances 0.000 claims abstract description 19
- 241000218176 Corydalis Species 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 241000239226 Scorpiones Species 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims description 73
- 201000008275 breast carcinoma Diseases 0.000 claims description 48
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 239000012141 concentrate Substances 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 210000000582 semen Anatomy 0.000 claims description 33
- 238000010298 pulverizing process Methods 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 25
- 241000522620 Scorpio Species 0.000 claims description 18
- 239000009490 scorpio Substances 0.000 claims description 18
- 244000285790 Cyperus iria Species 0.000 claims description 17
- 241001646826 Isodon rubescens Species 0.000 claims description 17
- 241000222640 Polyporus Species 0.000 claims description 16
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 16
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 47
- 206010028980 Neoplasm Diseases 0.000 abstract description 40
- 208000002193 Pain Diseases 0.000 abstract description 25
- 230000036407 pain Effects 0.000 abstract description 25
- 231100000614 poison Toxicity 0.000 abstract description 14
- 206010030113 Oedema Diseases 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 10
- 239000003440 toxic substance Substances 0.000 abstract description 10
- 208000004880 Polyuria Diseases 0.000 abstract description 9
- 230000035619 diuresis Effects 0.000 abstract description 9
- 210000000952 spleen Anatomy 0.000 abstract description 8
- 230000003213 activating effect Effects 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 238000012546 transfer Methods 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 230000001914 calming effect Effects 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000559228 Bolboschoenus yagara Species 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 240000005629 Curcuma phaeocaulis Species 0.000 abstract 1
- 235000003391 Curcuma phaeocaulis Nutrition 0.000 abstract 1
- 241000208368 Euonymus alatus Species 0.000 abstract 1
- 241001598107 Imperata Species 0.000 abstract 1
- 240000003146 Lobelia chinensis Species 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 235000015506 Solanum lyratum Nutrition 0.000 abstract 1
- 241000585552 Solanum lyratum Species 0.000 abstract 1
- 235000002594 Solanum nigrum Nutrition 0.000 abstract 1
- 240000002307 Solanum ptychanthum Species 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 235000009508 confectionery Nutrition 0.000 description 13
- 238000011580 nude mouse model Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 230000008961 swelling Effects 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 208000025747 Rheumatic disease Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000000552 rheumatic effect Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- -1 when decocting Substances 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 239000002435 venom Substances 0.000 description 3
- 210000001048 venom Anatomy 0.000 description 3
- 231100000611 venom Toxicity 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000358276 Cryptoprocta ferox Species 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 206010048612 Hydrothorax Diseases 0.000 description 2
- 206010024453 Ligament sprain Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- 206010044302 Tracheitis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 206010006189 Breast cancer in situ Diseases 0.000 description 1
- 241000239225 Buthidae Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000037162 Ductal Breast Carcinoma Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940127021 low-dose drug Drugs 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine composition for treating breast cancer. Various natural Chinese herbs are adopted as raw materials. In the raw material components, radix codonopsis and bighead atractylodes rhizomes have the effect of improving the immunity of the human body, radix astragali has the effects of tonifying qi and the spleen, and inducing diuresis to alleviate edema, radix angelica sinensis, tubers of scirpus yagara ohw, curcuma phaeocaulis valeton, winged euonymus twigs and rhizoma corydalis have the effect of activating blood circulation to dissipate stasis, and radix actinidiae chinensis, spreading hedyotis herb, Chinese lobelia herb, lalang grass rhizomes, black nightshade herb, solanum lyratum thunb, herba rabdosiae rubescentis and coix seeds have the effect of clearing away heat and toxic materials, and have the effects of calming endogenous wind and relieving phlegm, clearing and activating the channels and collaterals, and counteracting toxic substances and removing stasis with the assistance of scorpions; all the medicine materials are in coordinate compatibility, mutually supplement one another, jointly achieve the effects of suppressing tumors and removing stasis, activating blood circulation to dissipate stasis, and activating meridians to stop pain, and are remarkable in treatment effect on breast cancer and capable of treating both the symptoms and root causes; besides, the medicine composition is a pure traditional Chinese preparation, is free of toxic or side effects, and improves the constitution of a patient, improves the immunity and relieves toxicity while inhibiting the growth and transfer of cancer cells, and thus the anti-cancer treatment effect is enhanced.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to a kind of pharmaceutical composition treating breast carcinoma and its preparation method and application.
Background technology
Breast carcinoma is one of modal malignant tumor of women, and according to statistics, sickness rate accounts for the 7-10% of the various malignant tumor of whole body, is only second to uterus carcinoma in gynaecopathia.Its morbidity is the most relevant with heredity, usually occur in the malignant tumor of breast glandular epithelium tissue, it is that one has a strong impact on one of the most life-threatening modal malignant tumor of women's physical and mental health, between 40-60 year, women's sickness rate before and after menopause is higher, and the patient with breast cancer the most also having about 1.2% is male.
Along with meState is nationalEconomic development, the raising of people's living standard, the sickness rate of breast carcinoma is also in the trend risen year by year, and big and medium-sized cities are especially prominent.Tianjin and two places, Shanghai data show, within 1988 to 1992 years, compare with 1981 to nineteen eighty-two, and breast cancer incidence adds 35.2%.Beijing is from the beginning of 1978, and breast carcinoma has become as the malignant tumor that women's sickness rate is the highest, the most also rises with the speed of annual 2.4%, and present annual morbidity has reached 4-10 ten thousand people.
Breast carcinoma be breast glandular epithelium under multiple cancerigenic factor effect, there occurs gene mutation, cause hyperplasia out of control.At present, western medical treatment breast carcinoma mainly uses hands art, radiotherapy, the methods such as chemotherapy, but these methods are the most defective: (1) only has breast carcinoma of early stage patient just can carry out operative treatment, although mammary gland is not the important organ of human life activity, breast cancer in situ is the most fatal for theory, can reach to cure by surgical resection, but because mammary glandular cell just loses Normocellular characteristic after undergoing mutation, organizational structure is disorderly, cell connects loose, cancerous cell is easy to come off free, whole body is sent out with blood or lymph fluid etc., form far-end transfer in early days, the biggest difficulty is added to the clinical cure of breast carcinoma；(2) radiation and chemotherapy can only the misery of respite patient, it is impossible to thoroughly eradicates disease, has obvious limitation；(3) patient is after excision, radiation and chemotherapy, easily causes sequela, and additionally operative treatment is all huge to the injury of patient body and soul, has a strong impact on quality of life of patients.
Summary of the invention
In order to solve the problems referred to above that prior art exists, the invention provides a kind of effective prolongation patient vitals life cycle, the pharmaceutical composition for the treatment of breast carcinoma alleviating patient suffering and its preparation method and application.
The technical solution adopted in the present invention is:
A kind of pharmaceutical composition treating breast carcinoma, raw material components includes:
nullRadix Codonopsis 18-22 weight portion、Rhizoma Atractylodis Macrocephalae 18-22 weight portion、Radix Astragali 56-64 weight portion、Radix Actinidiae Chinensis 56-64 weight portion、Radix Angelicae Sinensis 10-20 weight portion、Spica Prunellae 10-20 weight portion、Radix Paeoniae Alba 10-20 weight portion、Cyperus iria L. rhizoma scirpi 9-11 weight portion、Rhizoma Curcumae 9-11 weight portion、Polyporus 56-64 weight portion、Poria 56-64 weight portion、Ramulus Euonymi 9-11 weight portion、Herba Hedyotidis Diffusae 9-11 weight portion、Rhizoma Corydalis 9-11 weight portion、Cortex Cinnamomi 15-25 weight portion、Radix Rehmanniae Preparata 45-60 weight portion、Herba Lobeliae Chinensis 9-11 weight portion、Rhizoma Imperatae 9-11 weight portion、Herba Solani Nigri 56-64 weight portion、Herba Solani Lyrati 56-64 weight portion、Rabdosia rubescens 56-64 weight portion、Scorpio 5-7 weight portion and Semen Coicis 56-64 weight portion.
The raw material components of the pharmaceutical composition of the most described treatment breast carcinoma includes: Radix Codonopsis 20 weight portion, the Rhizoma Atractylodis Macrocephalae 20 weight portion, the Radix Astragali 60 weight portion, Radix Actinidiae Chinensis 60 weight portion, Radix Angelicae Sinensis 15 weight portion, Spica Prunellae 15 weight portion, the Radix Paeoniae Alba 15 weight portion, cyperus iria L. rhizoma scirpi 10 weight portion, Rhizoma Curcumae 10 weight portion, Polyporus 60 weight portion, Poria 60 weight portion, Ramulus Euonymi 10 weight portion, Herba Hedyotidis Diffusae 10 weight portion, Rhizoma Corydalis 10 weight portion, Cortex Cinnamomi 20 weight portion, Radix Rehmanniae Preparata 54 weight portion, Herba Lobeliae Chinensis 10 weight portion, Rhizoma Imperatae 10 weight portion, Herba Solani Nigri 60 weight portion, Herba Solani Lyrati 60 weight portion, Rabdosia rubescens 60 weight portion, Scorpio 6 weight portion and Semen Coicis 60 weight portion.
A kind of method of pharmaceutical composition preparing described treatment breast carcinoma, comprises the steps:
(1) weigh described Radix Codonopsis and the Rhizoma Atractylodis Macrocephalae, be dried respectively, after pulverization process, obtain Radix Codonopsis fine powder and Rhizoma Atractylodis Macrocephalae fine powder；Carry out described Radix Codonopsis fine powder and Rhizoma Atractylodis Macrocephalae fine powder being sufficiently mixed uniformly, fry to deep yellow with Testa Tritici afterwards, remove Testa Tritici, obtain the first premix material, stand-by；
(2) weigh the described Radix Astragali, Radix Actinidiae Chinensis, Radix Angelicae Sinensis, Spica Prunellae, the Radix Paeoniae Alba, cyperus iria L. rhizoma scirpi, Rhizoma Curcumae, Polyporus and Poria successively and be sufficiently mixed, obtaining mixed material；In described mixed material, add 5-10 times of quality water decoct, obtain decoction liquor；
(3) carry out step (2) described decoction liquor successively filtering, concentrating, obtain the concentrate that relative density is 1.1-1.3g/ml, described concentrate is dried, pulverizes, obtain the second premix material, stand-by；
(4) described Ramulus Euonymi, Herba Hedyotidis Diffusae, Rhizoma Corydalis, Cortex Cinnamomi, Radix Rehmanniae Preparata, Herba Lobeliae Chinensis, Rhizoma Imperatae, Herba Solani Nigri, Herba Solani Lyrati and Rabdosia rubescens are weighed successively, through being separately dried, after pulverization process, obtain the fine powder of above-mentioned each raw material, the fine powder of described each raw material is sufficiently mixed, obtains mixed material；In described mixed material, add the ethanol of 6-9 times of volume and 40-80 DEG C of reflux, extract, 1-2h, after reclaiming ethanol, obtain extracting solution；
(5) carry out step (4) described extracting solution successively filtering, concentrating, obtain the concentrate that relative density is 1.2-1.4g/ml, described concentrate is dried, pulverizes, obtain the 3rd premix material, stand-by；
(6) weigh described Scorpio, after drying, pulverization process, obtain scorpion powder, stand-by；
(7) weigh described Semen Coicis, after drying, pulverization process, obtain Semen Coicis powder, stand-by；
(8) carry out described for step (1) the first premix material, described second premix material of step (3), step (5) the 3rd premix material, step (6) described scorpion powder and step (7) described Semen Coicis powder being sufficiently mixed uniformly, obtain the pharmaceutical composition of described treatment breast carcinoma.
In step (1), the granularity of described Radix Codonopsis fine powder and Rhizoma Atractylodis Macrocephalae fine powder is 110-130 mesh.
In step (2), described decoction repeats three times, the decoction liquor of three gained is merged；The time every time decocted is 30-60min.
In step (3), the temperature carrying out described concentration is 70-90 DEG C, carries out described dry temperature and is 110-130 DEG C.
In step (4), the granularity of the fine powder of described each raw material is 110-130 mesh；The volume fraction of described ethanol is 75-95%.
In step (5), the temperature carrying out described concentration is 60-80 DEG C, carries out described dry temperature and is 100-120 DEG C.
The granularity of described scorpion powder and described Semen Coicis powder is 110-130 mesh.
Described pharmaceutical composition is for preparing the application in treatment breast cancer medicines.
It should be noted that the dosage form of the pharmaceutical composition for the treatment of breast carcinoma of the present invention can be tablet, granule or capsule.To those skilled in the art, according to dosage form needs, select conventional pharmaceutical necessities to make applicable medicament, belong to routine techniques.
For the ease of understanding the present invention, below the raw material in the present invention and drug effect are further elaborated.
Radix Codonopsis, sweet in the mouth, property is put down.There is effect of strengthening the spleen and tonifying the lung, supplementing QI for promoting the production of body fluid.For treating weakness of the spleen and stomach, anorexia and loose stool, limbs fatigue, the deficiency of the lung is breathed with cough, spontaneous perspiration of breathing hard, feeble QI two lose all cards.
The Rhizoma Atractylodis Macrocephalae, bitter in the mouth, sweet, warm in nature.There is invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive effect.For treating deficiency-weakness of spleen-QI, spiritlessness and weakness, the few abdominal distention of lack of appetite, big loose stool is thin, fluid-retention stagnating in the interior, dysuria, edema, dizziness due to fluid-retention, and temperature numbness is ached, spontaneous sweating due to deficiency of QI, frequent fetal movement.
The Radix Astragali, sweet in the mouth, warm in nature.There is benefiting QI for strengthening the superficies, arresting sweating admittedly take off, hold in the palm skin ulcer granulation promoting, effect of inducing diuresis to remove edema.Weak for treating the deficiency of vital energy, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, carbuncle difficulty is burst, and bursts for a long time and does not holds back, blood deficiency and yellow complexion, and interior-heat is quenched one's thirst, chronic nephritis, albuminuria, diabetes etc..
Radix Actinidiae Chinensis, sour in the mouth, puckery, cool in nature.Having heat-clearing and toxic substances removing, clearing away heat-damp and promoting diuresis, preventing tumor is anticancer, expelling wind and removing dampness, diuresis is stopped blooding, and effect of removing toxic substances and promoting subsidence of swelling is used for treating the diseases such as dyspepsia, vomiting, rheumatic arthralgia, rheumatic ostalgia, Alimentary Tract Cancer, digestive tract tumor, carbuncle and ulcer furuncle, rheumatic ostalgia and jaundice.
Radix Angelicae Sinensis, sweet in the mouth, pungent, bitter, warm in nature.Have and enrich blood, invigorate blood circulation, menstruction regulating and pain relieving, moisturize effect of laxation.The all cards of main blood deficiency；For treating blood deficiency and yellow complexion, dizziness cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.
Spica Prunellae, bitter in the mouth, pungent, cold in nature.There is liver heat removing and eyesight improving, effect of powder detoxifcation.For treating conjunctival congestion and swelling pain, mesh pearl nyctalgia, dizziness of having a headache, scrofula, goiter, acute mastitis swells and ache；Thyromegaly, tuberculous lymphadenitis, cyclomastopathy, hypertension.
The Radix Paeoniae Alba, bitter in the mouth, acid, cold nature.Have and nourish blood and seek, relieving spasm to stop pain, effect of yin fluid astringing suppressing the hyperactive liver.For treating menoxenia, abdominal pain during menstruation, metrorrhagia, spontaneous perspiration, night sweat, coerce rib epigastric pain, limb pain twin, headache, dizziness.
Cyperus iria L. rhizoma scirpi, acrid in the mouth, hardship, property is put down.There is removing blood stasis circulation of qi promoting, effect of removing food stagnancy pain relieving.For treating lump in the abdomen mass in the abdomen, blood stasis amenorrhea, food stagnation distending pain.
Rhizoma Curcumae, acrid in the mouth, hardship, warm in nature.There is circulation of qi promoting removing blood stasis, effect of removing food stagnancy pain relieving.Pained for treating vim and vigour, eating accumulation, abdominal distention, amenorrhea due to stagnation of blood, dysmenorrhea, lump in the abdomen tumor mass in the abdomen, traumatic injury.
Polyporus, sweet in the mouth, light, property is put down.There is effect of diuresis eliminating dampness by diuresis.For treating dysuria, edema distension, tinea pedis, have loose bowels, drench, turbid, leukorrhagia.
Poria, sweet in the mouth, light, property is put down.There is eliminating dampness and diuresis, invigorating the spleen and regulating the stomach, effect of mind tranquilizing and the heart calming.For treating dysuria, edema distension, phlegm retention cough with dyspnea, vomiting, insufficiency of the spleen lack of appetite, have loose bowels, palpitation and restlessness, insomnia forgetfulness, nebulousurine of passing out semen.
Ramulus Euonymi, acrid in the mouth, hardship, cold in nature.There is removing blood stasis stimulate the menstrual flow, removing toxic substances and promoting subsidence of swelling, effect of parasite killing.For treat lump in the abdomen caking, trusted subordinate's pain, amenorrhea, dysmenorrhea, metrorrhagia and metrostaxis, puerperal the stagnant stomachache of the stasis of blood, retention of lochia, hernia, severe and migratory arthralgia arthralgia pain, skin ulcer swell, traumatic pain, abdominal pain due to worm stagnation, burn and scald, venom.
Herba Hedyotidis Diffusae, bitter in the mouth, sweet, cold in nature, nontoxic.There is heat-clearing and toxic substances removing, effect of dampness removing.For treating dyspnea and cough due to lung-heat, laryngopharynx swelling and pain, acute appendicitis, furuncle and phyma skin infection, venom, the puckery pain of pyretic stranguria, edema, dysentery；Enteritis, jaundice due to damp-heat, cancerous protuberance.
Rhizoma Corydalis, acrid in the mouth, hardship, warm in nature, nontoxic.Have and invigorate blood circulation, dissipating blood stasis, regulate the flow of vital energy, effect of pain relieving.For treating trusted subordinate's all pains of waist knee joint, menoxenia, lump in the abdomen, metrorrhagia, puerperal blood faints；Lochiorrhea, traumatic injury.
Cortex Cinnamomi, acrid in the mouth, sweet, property heat.There is benefit fire supporing yang, let the fire back to its origin, dispersing cold for relieving pain, effect of warming the meridian and promoting blood circulation.For treating sexual impotence, cold womb, chills and pain of the waist and kness, suffer from a deficiency of the kidney and breathe heavily, dizziness due to yang deficiency, conjunctival congestion pharyngalgia, trusted subordinate's cold type of pain, deficiency and coldness vomiting and diarrhoea, colic of cold type, renal mass, amenorrhea, dysmenorrhea.
Radix Rehmanniae Preparata, sweet in the mouth, warm in nature.Having and enrich blood moist, benefit essence fills out effect of marrow.Sallow for treating blood tiger, dizziness cardiopalmus, menoxenia, collapse more than, hepatic and renal YIN deficiency, hectic fever night sweat, sexual impotence of passing out semen, infertility, soreness of the waist and knees, Hiccough and deaf, the head is dim-sighted, and early whitening of beard and hair is quenched one's thirst, constipation, dyspnea with rapid and short breath of suffering from a deficiency of the kidney.
Herba Lobeliae Chinensis, sweet in the mouth, property is put down.There is diuretic, detumescence, effect of removing toxic substances, it is used for treating jaundice, edema, tympanites, has loose bowels, dysentery, snakebite, furuncle, toxic swelling, eczema, tinea, osteopatia sprain swells and ache.
Rhizoma Imperatae, sweet in the mouth, cold in nature.There is cooling blood for hemostasis, clearing away heat and promoting production of body fluid, effect of inducing diuresis for treating stranguria syndrome.It is mainly used to treatment heat in blood hemorrhage, calentura excessive thirst, gastric heat vomiting, dyspnea and cough due to lung-heat, the puckery pain of dribbling urination, edema, jaundice.
Herba Solani Nigri, bitter in the mouth, micro-sweet, cold in nature, slightly poisonous.There is heat clearing away, removing toxic substances, invigorate blood circulation, effect of detumescence.For treating furuncle, carbuncle, erysipelas, osteopatia sprain, chronic tracheitis, acute nephritis.
Herba Solani Lyrati, bitter in the mouth, cold in nature, slightly poisonous.Have heat-clearing and toxic substances removing, relieve internal heat anticancer effect.For treating laryngopharynx swelling and pain, blurred vision is red, mastitis, rib adenitis, scabies, scabies pruritus.
Rabdosia rubescens, bitter in the mouth, sweet, cold nature.There is heat-clearing and toxic substances removing, effect of promoting blood circulation and stopping pain.For treating laryngopharynx swelling and pain, headache due to common cold, tracheitis, chronic hepatitis, rheumatic arthritis, snake bite and insect sting.To esophagocardial carcinoma, hepatocarcinoma, breast carcinoma, rectal cancer have certain mitigation.
Scorpio cries again Scorpio, for the dry entirety of Buthidae animal Scorpio.Acrid in the mouth, property is put down, poisonous.Have and expelling wind and relieving convulsion, removing obstruction in the collateral to relieve pain, effect of rose poison eliminating stagnation.For treating infantile convulsion, tic spasm, middle air portHemiplegia, tetanus, rheumatoid arthritis stubborn, migraine and general headache, toothache, deaf, carbuncle sore tumefacting virus, scrofula sucutaneous nodule, venom, burn, rubella, stubborn dermatitis.
Semen Coicis, sweet in the mouth, light, cold nature.There is dampness removing spleen invigorating, arthralgia relieving by relaxing muscles and tendons, effect of clearing away heat and discharging pus.For treating edema, tinea pedis, dribbling urination, damp-warm diseases, leukorrhagia of having loose bowels, rheumatic arthralgia, muscle arteries and veins contracture, lung abscess, acute appendicitis, verruca plana.
The invention have the benefit that
1, the pharmaceutical composition for the treatment of breast carcinoma of the present invention, use multiple natural Chinese medicinal herb as raw material, Radix Codonopsis in raw material components, the Rhizoma Atractylodis Macrocephalae has the effect improving body immunity, the Radix Astragali has air making-up and spleen enlivening, effect of inducing diuresis to remove edema, and the Radix Astragali consumption that the present invention limits is conducive to being obviously improved the immunologic function of tumor patient, Radix Angelicae Sinensis in raw material components, cyperus iria L. rhizoma scirpi, Rhizoma Curcumae, Ramulus Euonymi, Rhizoma Corydalis has effect of activating blood circulation to dissipate blood stasis, it is thus possible to be effectively improved blood clotting hypercoagulability, adjust connective tissue metabolism, alleviate the connective fiber that radiotherapy causes, there is anti-infectious function, be conducive to significantly improving anti-swollen curative effect；Radix Actinidiae Chinensis in raw material components, Herba Hedyotidis Diffusae, Herba Lobeliae Chinensis, Rhizoma Imperatae, Herba Solani Nigri, Herba Solani Lyrati, Rabdosia rubescens, Semen Coicis has effect of heat-clearing and toxic substances removing, it is aided with Scorpio there is endogenous wind stopping to stop expectorant, dredge the meridian passage, effect of dispersing pathogen accumulation, compatibility coordinated by above-mentioned all medicines, mutually gain, jointly play tumor suppression eliminating stagnation, activating blood circulation to dissipate blood stasis, the effect of removing obstruction in the collateral to relieve pain, treatment breast carcinoma effect is obvious, treating both the principal and secondary aspects of a disease, and pure Chinese medicinal preparation has no side effect, patient's body constitution is improved while the growth and transfer of anticancer, improve immunity, alleviate toxicity, thus strengthen anticancer therapeutic.Additionally, Chinese medicine composition of the present invention and radiotherapy, chemotherapy and operative treatment are combined, while heightening the effect of a treatment, effectively alleviate the toxic and side effects of radiotherapy, chemotherapeutics, energy symptom management, effectively extend patient vitals's life cycle, alleviate patient suffering, improve life in patients.
2, the preparation method of the pharmaceutical composition for the treatment of breast carcinoma of the present invention, by Radix Codonopsis and Rhizoma Atractylodis Macrocephalae Testa Tritici being fried, and obtains the mixture of Radix Codonopsis (parched) and Rhizoma Atractylodis Macrocephalae (parched) as the first premix material；nullBy with the Radix Astragali、Radix Actinidiae Chinensis、Radix Angelicae Sinensis、Spica Prunellae、The Radix Paeoniae Alba、Cyperus iria L. rhizoma scirpi、Rhizoma Curcumae、Polyporus and Poria are as raw material，Decoct successively、Filter、Concentrate、It is dried、Pulverizing obtains the second premix material，By with Ramulus Euonymi、Herba Hedyotidis Diffusae、Rhizoma Corydalis、Cortex Cinnamomi、Radix Rehmanniae Preparata、Herba Lobeliae Chinensis、Rhizoma Imperatae、Herba Solani Nigri、Herba Solani Lyrati and Rabdosia rubescens are as raw material，Carry out alcohol extraction successively、Filter、Concentrate、It is dried、Pulverizing obtains the 3rd premix material，Afterwards by the first premix material、Second premix material、3rd premix material mixes，And add scorpion powder and Semen Coicis powder，It is sufficiently mixed uniformly，In final prepared described pharmaceutical composition，The effective ingredient of above-mentioned various raw material is able to maximum reservation，Drug effect is worked in coordination with performance，There is tumor suppression eliminating stagnation、Activating blood circulation to dissipate blood stasis、The effect of removing obstruction in the collateral to relieve pain，Treatment breast carcinoma effect is obvious，Treating both the principal and secondary aspects of a disease，And pure Chinese medicinal preparation has no side effect，Patient's body constitution is improved while the growth and transfer of anticancer，Improve immunity，Alleviate toxicity，Thus strengthen anticancer therapeutic.
Accompanying drawing explanation
Fig. 1It it is each comparison organizing nude mice tumor mass volume after treatmentFigure。
Detailed description of the invention
With 1 weight portion generation in example belowTable 1g。
Embodiment 1
The present embodiment provides a kind of pharmaceutical composition treating breast carcinoma, and raw material components includes:
Radix Codonopsis 18 weight portion, the Rhizoma Atractylodis Macrocephalae 22 weight portion, the Radix Astragali 56 weight portion, Radix Actinidiae Chinensis 64 weight portion, Radix Angelicae Sinensis 10 weight portion, Spica Prunellae 20 weight portion, the Radix Paeoniae Alba 10 weight portion, cyperus iria L. rhizoma scirpi 11 weight portion, Rhizoma Curcumae 9 weight portion, Polyporus 64 weight portion, Poria 56 weight portion, Ramulus Euonymi 11 weight portion, Herba Hedyotidis Diffusae 9 weight portion, Rhizoma Corydalis 11 weight portion, Cortex Cinnamomi 15 weight portion, Radix Rehmanniae Preparata 60 weight portion, Herba Lobeliae Chinensis 9 weight portion, Rhizoma Imperatae 11 weight portion, Herba Solani Nigri 56 weight portion, Herba Solani Lyrati 64 weight portion, Rabdosia rubescens 56 weight portion, Scorpio 7 weight portion and Semen Coicis 56 weight portion.
Further, the preparation method of the pharmaceutical composition of described treatment breast carcinoma, comprise the steps:
(1) weigh described Radix Codonopsis and the Rhizoma Atractylodis Macrocephalae, be dried respectively, after pulverization process, obtain granularity and be Radix Codonopsis fine powder and the Rhizoma Atractylodis Macrocephalae fine powder of 110 mesh；Carry out described Radix Codonopsis fine powder and Rhizoma Atractylodis Macrocephalae fine powder being sufficiently mixed uniformly, fry to deep yellow with 60 DEG C of Testa Tritici afterwards, remove Testa Tritici, obtain the first premix material, stand-by；
(2) weigh the described Radix Astragali, Radix Actinidiae Chinensis, Radix Angelicae Sinensis, Spica Prunellae, the Radix Paeoniae Alba, cyperus iria L. rhizoma scirpi, Rhizoma Curcumae, Polyporus and Poria successively and be sufficiently mixed, obtaining mixed material；In described mixed material, add 5 times of quality water be heated to boiling the most with high heat, then slow fire carries out decocting 30min, obtains decoction liquor；
(3) step (2) described decoction liquor being filtered, filtrate concentrates at 70 DEG C, obtains the concentrate that relative density is 1.1g/ml, after described concentrate is dried 0.5h at 110 DEG C, pulverizes, obtains the second premix material, stand-by；
(4) described Ramulus Euonymi, Herba Hedyotidis Diffusae, Rhizoma Corydalis, Cortex Cinnamomi, Radix Rehmanniae Preparata, Herba Lobeliae Chinensis, Rhizoma Imperatae, Herba Solani Nigri, Herba Solani Lyrati and Rabdosia rubescens are weighed successively, through being separately dried, after pulverization process, obtain granularity and be the fine powder of the 110 above-mentioned each raw materials of purpose, the fine powder of described each raw material is sufficiently mixed, obtains mixed material；In described mixed material, add the ethanol (volume fraction is 75%) of 6 times of volumes and 40 DEG C of reflux, extract, 2h, after reclaiming ethanol, obtain extracting solution；
(5) after being filtered by step (4) described extracting solution, filtrate concentrates at 60 DEG C, obtains the concentrate that relative density is 1.2g/ml, after described concentrate is dried 1h at 100 DEG C, pulverizes, obtains the 3rd premix material, stand-by；
(6) weigh described Scorpio, after drying, pulverization process, obtain the scorpion powder that granularity is 110 mesh, stand-by；
(7) weigh described Semen Coicis, after drying, pulverization process, obtain the Semen Coicis powder that granularity is 110 mesh, stand-by；
(8) carry out described for step (1) the first premix material, described second premix material of step (3), step (5) the 3rd premix material, step (6) described scorpion powder and step (7) described Semen Coicis powder being sufficiently mixed uniformly, obtain the pharmaceutical composition of described treatment breast carcinoma.
Embodiment 2
The present embodiment provides a kind of pharmaceutical composition treating breast carcinoma, and raw material components includes:
Radix Codonopsis 22 weight portion, the Rhizoma Atractylodis Macrocephalae 18 weight portion, the Radix Astragali 64 weight portion, Radix Actinidiae Chinensis 56 weight portion, Radix Angelicae Sinensis 20 weight portion, Spica Prunellae 10 weight portion, the Radix Paeoniae Alba 20 weight portion, cyperus iria L. rhizoma scirpi 9 weight portion, Rhizoma Curcumae 11 weight portion, Polyporus 56 weight portion, Poria 64 weight portion, Ramulus Euonymi 9 weight portion, Herba Hedyotidis Diffusae 11 weight portion, Rhizoma Corydalis 9 weight portion, Cortex Cinnamomi 25 weight portion, Radix Rehmanniae Preparata 45 weight portion, Herba Lobeliae Chinensis 11 weight portion, Rhizoma Imperatae 9 weight portion, Herba Solani Nigri 64 weight portion, Herba Solani Lyrati 56 weight portion, Rabdosia rubescens 64 weight portion, Scorpio 5 weight portion and Semen Coicis 64 weight portion.
Further, the preparation method of the pharmaceutical composition of described treatment breast carcinoma, comprise the steps:
(1) weigh described Radix Codonopsis and the Rhizoma Atractylodis Macrocephalae, be dried respectively, after pulverization process, obtain granularity and be Radix Codonopsis fine powder and the Rhizoma Atractylodis Macrocephalae fine powder of 130 mesh；Carry out described Radix Codonopsis fine powder and Rhizoma Atractylodis Macrocephalae fine powder being sufficiently mixed uniformly, fry to deep yellow with 80 DEG C of Testa Tritici afterwards, remove Testa Tritici, obtain the first premix material, stand-by；
(2) weigh the described Radix Astragali, Radix Actinidiae Chinensis, Radix Angelicae Sinensis, Spica Prunellae, the Radix Paeoniae Alba, cyperus iria L. rhizoma scirpi, Rhizoma Curcumae, Polyporus and Poria successively and be sufficiently mixed, obtaining mixed material；In described mixed material, add 10 times of quality water, be heated to boiling the most with high heat, then carry out decocting 60min with slow fire, obtain decoction liquor；
(3) step (2) described decoction liquor being filtered, filtrate concentrates at 90 DEG C, obtains the concentrate that relative density is 1.3g/ml, after described concentrate is dried 1.5h at 130 DEG C, pulverizes, obtains the second premix material, stand-by；
(4) described Ramulus Euonymi, Herba Hedyotidis Diffusae, Rhizoma Corydalis, Cortex Cinnamomi, Radix Rehmanniae Preparata, Herba Lobeliae Chinensis, Rhizoma Imperatae, Herba Solani Nigri, Herba Solani Lyrati and Rabdosia rubescens are weighed successively, through being separately dried, after pulverization process, obtain granularity and be the fine powder of the 130 above-mentioned each raw materials of purpose, the fine powder of described each raw material is sufficiently mixed, obtains mixed material；In described mixed material, add the ethanol (volume fraction is 95%) of 9 times of volumes and 80 DEG C of reflux, extract, 1h, after reclaiming ethanol, obtain extracting solution；
(5) after being filtered by step (4) described extracting solution, filtrate concentrates at 80 DEG C, obtains the concentrate that relative density is 1.4g/ml, after described concentrate is dried 2h at 120 DEG C, pulverizes, obtains the 3rd premix material, stand-by；
(6) weigh described Scorpio, after drying, pulverization process, obtain the scorpion powder that granularity is 130 mesh, stand-by；
(7) weigh described Semen Coicis, after drying, pulverization process, obtain the Semen Coicis powder that granularity is 130 mesh, stand-by；
(8) carry out described for step (1) the first premix material, described second premix material of step (3), step (5) the 3rd premix material, step (6) described scorpion powder and step (7) described Semen Coicis powder being sufficiently mixed uniformly, obtain the pharmaceutical composition of described treatment breast carcinoma.
Embodiment 3
The present embodiment provides a kind of pharmaceutical composition treating breast carcinoma, and raw material components includes:
Radix Codonopsis 20 weight portion, the Rhizoma Atractylodis Macrocephalae 20 weight portion, the Radix Astragali 60 weight portion, Radix Actinidiae Chinensis 60 weight portion, Radix Angelicae Sinensis 15 weight portion, Spica Prunellae 15 weight portion, the Radix Paeoniae Alba 15 weight portion, cyperus iria L. rhizoma scirpi 10 weight portion, Rhizoma Curcumae 10 weight portion, Polyporus 60 weight portion, Poria 60 weight portion, Ramulus Euonymi 10 weight portion, Herba Hedyotidis Diffusae 10 weight portion, Rhizoma Corydalis 10 weight portion, Cortex Cinnamomi 20 weight portion, Radix Rehmanniae Preparata 54 weight portion, Herba Lobeliae Chinensis 10 weight portion, Rhizoma Imperatae 10 weight portion, Herba Solani Nigri 60 weight portion, Herba Solani Lyrati 60 weight portion, Rabdosia rubescens 60 weight portion, Scorpio 6 weight portion and Semen Coicis 60 weight portion.
Further, the preparation method of the pharmaceutical composition of described treatment breast carcinoma, comprise the steps:
(1) weigh described Radix Codonopsis and the Rhizoma Atractylodis Macrocephalae, be dried respectively, after pulverization process, obtain granularity and be Radix Codonopsis fine powder and the Rhizoma Atractylodis Macrocephalae fine powder of 120 mesh；Carry out described Radix Codonopsis fine powder and Rhizoma Atractylodis Macrocephalae fine powder being sufficiently mixed uniformly, fry to deep yellow with 70 DEG C of Testa Tritici afterwards, remove Testa Tritici, obtain the first premix material, stand-by；
(2) weigh the described Radix Astragali, Radix Actinidiae Chinensis, Radix Angelicae Sinensis, Spica Prunellae, the Radix Paeoniae Alba, cyperus iria L. rhizoma scirpi, Rhizoma Curcumae, Polyporus and Poria successively and be sufficiently mixed, obtaining mixed material；Carrying out decocting three times by described mixed material water, when decocting, medicine is 1:6 with the mass ratio of water every time, and each decoction is all to be heated to boiling the most with high heat, then carries out decocting 45min with slow fire, obtains decoction liquor for three times and merges；
(3) decoction liquor after step (2) described merging being filtered, filtrate concentrates at 80 DEG C, obtains the concentrate that relative density is 1.2g/ml, after described concentrate is dried 1h at 120 DEG C, pulverizes, obtains the second premix material, stand-by；
(4) described Ramulus Euonymi, Herba Hedyotidis Diffusae, Rhizoma Corydalis, Cortex Cinnamomi, Radix Rehmanniae Preparata, Herba Lobeliae Chinensis, Rhizoma Imperatae, Herba Solani Nigri, Herba Solani Lyrati and Rabdosia rubescens are weighed successively, through being separately dried, after pulverization process, obtain granularity and be the fine powder of the 120 above-mentioned each raw materials of purpose, the fine powder of described each raw material is sufficiently mixed, obtains mixed material；The ethanol that described mixed material volume fraction is 80% is carried out reflux, extract, three times, during each reflux, extract, medicine is 1:8 with the ratio of the volume of ethanol, the temperature of reflux, extract, is 60 DEG C every time, the time of reflux, extract, is 1.5h, extract the liquid obtained for three times to merge, after reclaiming ethanol, obtain extracting solution；
(5) after being filtered by step (4) described extracting solution, filtrate concentrates at 70 DEG C, obtains the concentrate that relative density is 1.3g/ml, after described concentrate is dried 1.5h at 110 DEG C, pulverizes, obtains the 3rd premix material, stand-by；
(6) weigh described Scorpio, after drying, pulverization process, obtain the scorpion powder that granularity is 120 mesh, stand-by；
(7) weigh described Semen Coicis, after drying, pulverization process, obtain the Semen Coicis powder that granularity is 120 mesh, stand-by；
(8) carry out described for step (1) the first premix material, described second premix material of step (3), step (5) the 3rd premix material, step (6) described scorpion powder and step (7) described Semen Coicis powder being sufficiently mixed uniformly, obtain the pharmaceutical composition of described treatment breast carcinoma.
Embodiment 4
The present embodiment provides a kind of pharmaceutical composition treating breast carcinoma, and raw material components includes:
Radix Codonopsis 20 weight portion, the Rhizoma Atractylodis Macrocephalae 20 weight portion, the Radix Astragali 60 weight portion, Radix Actinidiae Chinensis 60 weight portion, Radix Angelicae Sinensis 15 weight portion, Spica Prunellae 15 weight portion, the Radix Paeoniae Alba 15 weight portion, cyperus iria L. rhizoma scirpi 10 weight portion, Rhizoma Curcumae 10 weight portion, Polyporus 60 weight portion, Poria 60 weight portion, Ramulus Euonymi 10 weight portion, Herba Hedyotidis Diffusae 10 weight portion, Rhizoma Corydalis 10 weight portion, Cortex Cinnamomi 20 weight portion, Radix Rehmanniae Preparata 54 weight portion, Herba Lobeliae Chinensis 10 weight portion, Rhizoma Imperatae 10 weight portion, Herba Solani Nigri 60 weight portion, Herba Solani Lyrati 60 weight portion, Rabdosia rubescens 60 weight portion, Scorpio 6 weight portion and Semen Coicis 60 weight portion.
Further, the preparation method of the pharmaceutical composition of described treatment breast carcinoma, comprise the steps:
(1) weigh described Radix Codonopsis and the Rhizoma Atractylodis Macrocephalae, be dried respectively, after pulverization process, obtain granularity and be Radix Codonopsis fine powder and the Rhizoma Atractylodis Macrocephalae fine powder of 120 mesh；Carry out described Radix Codonopsis fine powder and Rhizoma Atractylodis Macrocephalae fine powder being sufficiently mixed uniformly, fry to deep yellow with 70 DEG C of Testa Tritici afterwards, remove Testa Tritici, obtain the first premix material, stand-by；
(2) weigh the described Radix Astragali, Radix Actinidiae Chinensis, Radix Angelicae Sinensis, Spica Prunellae, the Radix Paeoniae Alba, cyperus iria L. rhizoma scirpi, Rhizoma Curcumae, Polyporus and Poria successively and be sufficiently mixed, obtaining mixed material；Carrying out decocting three times by described mixed material water, when decocting, medicine is 1:9 with the mass ratio of water every time, and each decoction is all to be heated to boiling the most with high heat, then uses slow fire boiling 60min, obtains decoction liquor for three times and merges；
(3) decoction liquor after step (2) described merging being filtered, filtrate concentrates at 80 DEG C, obtains the concentrate that relative density is 1.2g/ml, after described concentrate is dried 1h at 120 DEG C, pulverizes, obtains the second premix material, stand-by；
(4) described Ramulus Euonymi, Herba Hedyotidis Diffusae, Rhizoma Corydalis, Cortex Cinnamomi, Radix Rehmanniae Preparata, Herba Lobeliae Chinensis, Rhizoma Imperatae, Herba Solani Nigri, Herba Solani Lyrati and Rabdosia rubescens are weighed successively, through being separately dried, after pulverization process, obtain granularity and be the fine powder of the 120 above-mentioned each raw materials of purpose, the fine powder of described each raw material is sufficiently mixed, obtains mixed material；The ethanol that described mixed material volume fraction is 85% is carried out reflux, extract, three times, during each reflux, extract, medicine is 1:9 with the ratio of the volume of ethanol, the temperature of reflux, extract, is 65 DEG C every time, the time of reflux, extract, is 1.5h, extract the liquid obtained for three times to merge, after reclaiming ethanol, obtain extracting solution；
(5) after being filtered by step (4) described extracting solution, filtrate concentrates at 70 DEG C, obtains the concentrate that relative density is 1.3g/ml, after described concentrate is dried 1.5h at 110 DEG C, pulverizes, obtains the 3rd premix material, stand-by；
(6) weigh described Scorpio, after drying, pulverization process, obtain the scorpion powder that granularity is 120 mesh, stand-by；
(7) weigh described Semen Coicis, after drying, pulverization process, obtain the Semen Coicis powder that granularity is 120 mesh, stand-by；
(8) carry out described for step (1) the first premix material, described second premix material of step (3), step (5) the 3rd premix material, step (6) described scorpion powder and step (7) described Semen Coicis powder being sufficiently mixed uniformly, obtain the pharmaceutical composition of described treatment breast carcinoma.
Experimental example 1
The present inventor by applying the observation of this pharmaceutical composition to clinical 100 example patient with breast cancers, and wherein age minimum 39 years old, maximum 87 years old, is women.
Application process: oral, every day 1-2 time, each 2-3g, one week is a course for the treatment of.
Efficacy assessment standard:
Cure: clinical efficacy is notable, occur without Metastatic adenocarcinoma or metastasis (metastases) is wholly absent, 68 examples.
Effective: clinical symptoms is controlled, metastasis (metastases) progressively reduces, 27 examples.
Invalid: clinical symptoms is not improved 5 examples.Total effective rate 95%.
Typical clinical case:
Zhang, female, 46 years old, lives Rugao, Jiangsu Ru Cheng Wen Dingyuan, in 2008 because of left breast infiltrating duct carcinoma, cures in Shanghai tumorInstitute's rowLeft radical operation of mastocarcinoma, postoperative do 4 courses for the treatment of of regular chemotherapy, there is metastasis (metastases) in 1 year rear left axillary fossa and left thoracic wall, biopsy is reported as adenocarcinoma metastatic, taking pharmaceutical composition described in the embodiment of the present invention 3, altogether after 12 courses for the treatment of, metastasis (metastases) all disappears, check all normal through repeatedly B ultrasonic PETCT blood tumor marker, life is normal at present.
Lee, female, 56 years old, in August, 2006 cured at Shanghai xxInstitute's rowRight radical operation of mastocarcinoma, 3 courses for the treatment of of postoperative chemotherapy, in early October, 2009 B ultrasonic prompting hydrothorax, right axillary lymph tie many pieces, and biopsy turns out to be adenocarcinoma metastatic, again 3 courses for the treatment of of chemotherapy, and lymph node has no and reduces.Taking 3 courses for the treatment of of pharmaceutical composition described in the embodiment of the present invention 2, lymph node disappears, and hydrothorax disappears, and lives the best.
Clock, female, 87 years old, because of right swelling of the breast block 1 year, come institute in JIUYUE, 2010 to go to a doctor, doing the lump of 4cm*4cm size seen from the B ultrasonic prompting outside upper quadrant of right breast, B ultrasonic guides lower needle puncture biopsy to be reported as right breast carcinoma, because of patient's advanced age and be associated with multiple underlying diseases, old family's genus requires expectant treatment, taking 6 courses for the treatment of of pharmaceutical composition described in the embodiment of the present invention 4, current right swelling of the breast block is contracted to 1cm*1cm, and without any special discomfort.
Experimental example 2
Utilize the tumor suppression performance test that human breast carcinoma Xenografts in nude mice is grown by pharmaceutical composition described in the embodiment of the present invention 3
(1) material and method
1.1 cell strain
Breast cancer lines MDA-MB-231.
1.2 animal
Nude mice BALB/c-nu/nu, SPF level, female, 13-16g, to test and raise and all carry out in ultra-clean laminar-flow rack under the conditions of SPF level, the water of sterilization treatment and SPF level special feed freely absorb for animal.
The foundation of 1.3 animal models
By the RPMI-1640 culture medium containing 10% standard hyclone at 37 DEG C, 5%CO2Under the conditions of In vitro culture Breast cancer lines MDA-MB-231, cell attachment grow.Collect the cell (after passing on continue cultivate 24h) of exponential phase and be prepared as concentration and be about 1 × 107The single cell suspension of individual/ml.By every nude mice 0.2ml injection, it is inoculated in 40 right side of mice axillary fossas subcutaneous, after injection, gets final product (preventing cell suspension from oozing out from pin hole) a moment with pincet folder pin hole.Postoperative one-tenth tumor nude mice 36, tumor formation rate 90%.
1.4 animal packets, administration
With minor axis, the major diameter of vernier caliper measurement nude mouse tumor, calculate tumor volume=(major diameter × minor axis by Steel formula2)/2(cm3), treat about one week, tumor growth is averagely to 100mm3After, it is randomly divided into 6 groups, often group 6, respectively normal saline group (negative control group), 4 treatment groups, cyclophosphamide groups (positive controls), normal saline group gives normal saline (0.2ml) and carry out gastric infusion every day；4 therapeutic component, not with dosage gastric infusion every day of 50mg/kg, 100mg/kg, 200mg/kg, 500mg/kg, are respectively labeled as treating 1 group, treat 2 groups, treat 3 groups and treatment 4 groups；Cyclophosphamide group is with dosage gastric infusion every day of 30mg/kg.
The substantially index of 1.5 tumor growths
Use vernier caliper measurement tumor size before being administered after treatment every time, weigh nude mice body weight, after being administered 3 weeks, nude mice is put to death in dislocation of cervical vertebra, subcutaneous transplantation tumor is completely stripped out tumor tissues together with after birth, electronic balance weighs tumor weight, calculates tumor control rate (%)=(normal saline group average tumor weight-treatment group average tumor weight)/normal saline group average tumor weight × 100%.
2, experimental result
2.1 nude mice tumor mass volume (V=major diameter × minor axis2cm3/2)
Before treatment, each group tumor growth situation is basically identical, gross tumor volume indifference (P ＞ 0.05).After treatment, tumor perusal is shown inFig. 1, tumor mass volume statistics is shown inTable 1。
Result shows: compare with normal saline group, treats 1 group of (50mg/kg) no difference of science of statistics (P=0.286 ＞ 0.05)；Treat 2 groups (100mg/kg) and have significant difference (P=0.013 ＜ 0.05)；Treat 3 groups (200mg/kg) and have notable significant difference (P=0.008 ＜ 0.01)；Treat 4 groups (500mg/kg) and have notable significant difference (P=0.00099 ＜ 0.001)；Cyclophosphamide group (30mg/kg) has notable significant difference (P=0.00008 ＜ 0.001).
Table 1: each group nude mouse tumor average external volume after pharmaceutical intervention
| Packet | Number of cases | (cm after treatment3) |
| Normal saline group | 6 | 1.80±0.18 |
| Treat 1 group (50mg/kg) | 6 | 1.42±0.21 |
| Treat 2 groups (100mg/kg) | 6 | 1.10±0.11* |
| Treat 3 groups (200mg/kg) | 6 | 1.08±0.09** |
| Treat 4 groups (500mg/kg) | 6 | 0.78±0.09*** |
| Cyclophosphamide group (30mg/kg) | 6 | 0.54±0.07*** |
Note: compare with normal saline group: * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001.
2.2 nude mice tumor mass quality and tumor control rates
Tumor mass quality after treatmentSuch as table 2, result shows: compare with normal saline group, and treating 1 group (50mg/kg) has significant difference (P=0.023 ＜ 0.05)；Treat 2 groups (100mg/kg) and have significant difference (P=0.003 ＜ 0.01)；Treat 3 groups (200mg/kg) and have notable significant difference (P=0.0002 ＜ 0.001)；Treat 4 groups (500mg/kg) and have notable significant difference (P=0.00001 ＜ 0.001)；Cyclophosphamide group
(30mg/kg) there is notable significant difference (P ＜ 0.001).
Calculating tumor control rate according to formula " tumor control rate (%)=(normal saline group average tumor weight-treatment group average tumor weight)/normal saline group average tumor weight × 100% ", result is shown inTable 2.Result is pointed out: high dose medicament is stronger to tumor inhibition effect than low-dose drugs, and maximum dose level group (500mg/kg) reaches 47.8% to the suppression ratio of breast carcinoma subcutaneous transplanted tumor.
Table 2: each group transplanted tumor average quality after pharmaceutical interventionAnd tumor control rate
| Packet | Number of cases | Tumor quality (g) | Tumor control rate (%) |
| Normal saline group | 6 | 1.01±0.03 | - |
| Treat 1 group (50mg/kg) | 6 | 0.72±0.09* | 28.7 |
| Treat 2 groups (100mg/kg) | 6 | 0.69±0.07** | 31.7 |
| Treat 3 groups (200mg/kg) | 6 | 0.65±0.05** | 35.6 |
| Treat 4 groups (500mg/kg) | 6 | 0.49±0.05*** | 51.5 |
| Cyclophosphamide group (30mg/kg) | 6 | 0.34±0.03*** | 65.9 |
Note: compare with normal saline group: * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001.
Experimental result shows: the pharmaceutical composition for the treatment of breast carcinoma of the present invention can effectively suppress the growth of people's MDA-MB-231 Breast Carcinoma in nude mice subcutaneous transplantation tumor, tumor control rate compares with normal saline group that there were significant differences, increase difference especially as using dosage is the most obvious, thus illustrate that medicine composite for curing breast carcinoma effect of the present invention is obvious, treating both the principal and secondary aspects of a disease, and pure Chinese medicinal preparation has no side effect.
The present invention is not limited to above-mentioned preferred forms; anyone can draw other various forms of products under the enlightenment of the present invention; though but in its shape or structure, make any change, every have same as the present application or akin technical scheme, within all falling within protection scope of the present invention.
Claims (10)
1. the pharmaceutical composition treating breast carcinoma, it is characterised in that raw material components includes:
nullRadix Codonopsis 18-22 weight portion、Rhizoma Atractylodis Macrocephalae 18-22 weight portion、Radix Astragali 56-64 weight portion、Radix Actinidiae Chinensis 56-64 weight portion、Radix Angelicae Sinensis 10-20 weight portion、Spica Prunellae 10-20 weight portion、Radix Paeoniae Alba 10-20 weight portion、Cyperus iria L. rhizoma scirpi 9-11 weight portion、Rhizoma Curcumae 9-11 weight portion、Polyporus 56-64 weight portion、Poria 56-64 weight portion、Ramulus Euonymi 9-11 weight portion、Herba Hedyotidis Diffusae 9-11 weight portion、Rhizoma Corydalis 9-11 weight portion、Cortex Cinnamomi 15-25 weight portion、Radix Rehmanniae Preparata 45-60 weight portion、Herba Lobeliae Chinensis 9-11 weight portion、Rhizoma Imperatae 9-11 weight portion、Herba Solani Nigri 56-64 weight portion、Herba Solani Lyrati 56-64 weight portion、Rabdosia rubescens 56-64 weight portion、Scorpio 5-7 weight portion and Semen Coicis 56-64 weight portion.
The pharmaceutical composition for the treatment of breast carcinoma the most according to claim 1, it is characterized in that, raw material components includes: Radix Codonopsis 20 weight portion, the Rhizoma Atractylodis Macrocephalae 20 weight portion, the Radix Astragali 60 weight portion, Radix Actinidiae Chinensis 60 weight portion, Radix Angelicae Sinensis 15 weight portion, Spica Prunellae 15 weight portion, the Radix Paeoniae Alba 15 weight portion, cyperus iria L. rhizoma scirpi 10 weight portion, Rhizoma Curcumae 10 weight portion, Polyporus 60 weight portion, Poria 60 weight portion, Ramulus Euonymi 10 weight portion, Herba Hedyotidis Diffusae 10 weight portion, Rhizoma Corydalis 10 weight portion, Cortex Cinnamomi 20 weight portion, Radix Rehmanniae Preparata 54 weight portion, Herba Lobeliae Chinensis 10 weight portion, Rhizoma Imperatae 10 weight portion, Herba Solani Nigri 60 weight portion, Herba Solani Lyrati 60 weight portion, Rabdosia rubescens 60 weight portion, Scorpio 6 weight portion and Semen Coicis 60 weight portion.
3. the method for the pharmaceutical composition of the treatment breast carcinoma that one kind is prepared described in claim 1 or 2, it is characterised in that comprise the steps:
(1) weigh described Radix Codonopsis and the Rhizoma Atractylodis Macrocephalae, be dried respectively, after pulverization process, obtain Radix Codonopsis fine powder and Rhizoma Atractylodis Macrocephalae fine powder；Carry out described Radix Codonopsis fine powder and Rhizoma Atractylodis Macrocephalae fine powder being sufficiently mixed uniformly, fry to deep yellow with Testa Tritici afterwards, remove Testa Tritici, obtain the first premix material, stand-by；
(2) weigh the described Radix Astragali, Radix Actinidiae Chinensis, Radix Angelicae Sinensis, Spica Prunellae, the Radix Paeoniae Alba, cyperus iria L. rhizoma scirpi, Rhizoma Curcumae, Polyporus and Poria successively and be sufficiently mixed, obtaining mixed material；In described mixed material, add 5-10 times of quality water decoct, obtain decoction liquor；
(3) carry out step (2) described decoction liquor successively filtering, concentrating, obtain the concentrate that relative density is 1.1-1.3g/ml, described concentrate is dried, pulverizes, obtain the second premix material, stand-by；
(4) described Ramulus Euonymi, Herba Hedyotidis Diffusae, Rhizoma Corydalis, Cortex Cinnamomi, Radix Rehmanniae Preparata, Herba Lobeliae Chinensis, Rhizoma Imperatae, Herba Solani Nigri, Herba Solani Lyrati and Rabdosia rubescens are weighed successively, through being separately dried, after pulverization process, obtain the fine powder of above-mentioned each raw material, the fine powder of described each raw material is sufficiently mixed, obtains mixed material；In described mixed material, add the ethanol of 6-9 times of volume and 40-80 DEG C of reflux, extract, 1-2h, after reclaiming ethanol, obtain extracting solution；
(5) carry out step (4) described extracting solution successively filtering, concentrating, obtain the concentrate that relative density is 1.2-1.4g/ml, described concentrate is dried, pulverizes, obtain the 3rd premix material, stand-by；
(6) weigh described Scorpio, after drying, pulverization process, obtain scorpion powder, stand-by；
(7) weigh described Semen Coicis, after drying, pulverization process, obtain Semen Coicis powder, stand-by；
(8) carry out described for step (1) the first premix material, described second premix material of step (3), step (5) the 3rd premix material, step (6) described scorpion powder and step (7) described Semen Coicis powder being sufficiently mixed uniformly, obtain the pharmaceutical composition of described treatment breast carcinoma.
The preparation method of the pharmaceutical composition for the treatment of breast carcinoma the most according to claim 3, it is characterised in that in step (1), the granularity of described Radix Codonopsis fine powder and Rhizoma Atractylodis Macrocephalae fine powder is 110-130 mesh.
The preparation method of the pharmaceutical composition for the treatment of breast carcinoma the most according to claim 3, it is characterised in that in step (2), described decoction repeats three times, the decoction liquor of three gained is merged；The time every time decocted is 30-60min.
The preparation method of the pharmaceutical composition for the treatment of breast carcinoma the most according to claim 3, it is characterized in that, in step (3), the temperature carrying out described concentration is 70-90 DEG C, carrying out described dry temperature and be 110-130 DEG C, carrying out the described dry time is 0.5-1.5h.
The preparation method of the pharmaceutical composition for the treatment of breast carcinoma the most according to claim 3, it is characterised in that in step (4), the granularity of the fine powder of described each raw material is 110-130 mesh；The volume fraction of described ethanol is 75-95%.
The preparation method of the pharmaceutical composition for the treatment of breast carcinoma the most according to claim 3, it is characterized in that, in step (5), the temperature carrying out described concentration is 60-80 DEG C, carrying out described dry temperature and be 100-120 DEG C, carrying out the described dry time is 1-2h.
The preparation method of the pharmaceutical composition for the treatment of breast carcinoma the most according to claim 3, it is characterised in that the granularity of described scorpion powder and described Semen Coicis powder is 110-130 mesh.
Pharmaceutical composition the most according to claim 1 and 2 is for preparing the application in treatment breast cancer medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610286686.4A CN105816813A (en) | 2016-04-29 | 2016-04-29 | Medicine composition for treating breast cancer and preparing method and application of medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610286686.4A CN105816813A (en) | 2016-04-29 | 2016-04-29 | Medicine composition for treating breast cancer and preparing method and application of medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105816813A true CN105816813A (en) | 2016-08-03 |
Family
ID=56527940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610286686.4A Pending CN105816813A (en) | 2016-04-29 | 2016-04-29 | Medicine composition for treating breast cancer and preparing method and application of medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105816813A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106963919A (en) * | 2017-04-11 | 2017-07-21 | 新乡医学院 | It is a kind of for Chinese patent drug of hemostatic analgesia and its preparation method and application |
| CN111410641A (en) * | 2020-03-03 | 2020-07-14 | 黑龙江中医药大学 | Atractylodes macrocephala lactone polymer with antitumor activity and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926956A (en) * | 2009-06-24 | 2010-12-29 | 许东群 | Chinese medicinal powder for treating mazoitis, hyperplasia of mammary glands and breast cancer |
| CN103611057A (en) * | 2013-08-15 | 2014-03-05 | 陆少波 | Breast cancer capsule for treating breast cancer and preparation method therefor |
-
2016
- 2016-04-29 CN CN201610286686.4A patent/CN105816813A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926956A (en) * | 2009-06-24 | 2010-12-29 | 许东群 | Chinese medicinal powder for treating mazoitis, hyperplasia of mammary glands and breast cancer |
| CN103611057A (en) * | 2013-08-15 | 2014-03-05 | 陆少波 | Breast cancer capsule for treating breast cancer and preparation method therefor |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106963919A (en) * | 2017-04-11 | 2017-07-21 | 新乡医学院 | It is a kind of for Chinese patent drug of hemostatic analgesia and its preparation method and application |
| CN111410641A (en) * | 2020-03-03 | 2020-07-14 | 黑龙江中医药大学 | Atractylodes macrocephala lactone polymer with antitumor activity and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103550517B (en) | A kind of medicine of Hepatoma therapy | |
| CN104352776A (en) | Traditional Chinese medicine preparation for treating infertility caused by hypomenorrhea and preparation method thereof | |
| CN104043057A (en) | Traditional Chinese medicinal composition for treating lymph cancer | |
| CN103920034A (en) | Traditional Chinese medicine composition for alleviating side effects of chemotherapy of cancer patient and preparation method traditional Chinese medicine composition | |
| CN103550696A (en) | Medicine for treating lung cancer | |
| CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
| CN104383317A (en) | Chinese traditional medicine composition for treating liver cancer | |
| CN104225166A (en) | Chinese medicine composition for treating amenorrhea and preparation method thereof | |
| CN103690889A (en) | Traditional Chinese medicine decoction for treating stomach cancer | |
| CN106177811A (en) | A kind of external application Chinese medicine treating pernicious ascites pleural fluid and usage thereof | |
| CN105816813A (en) | Medicine composition for treating breast cancer and preparing method and application of medicine composition | |
| CN102274445A (en) | Cassia twig common burreed rhizome tumor eliminating pills | |
| CN104873828A (en) | Chinese herba preparation for treating radioactive skin injury and preparation method thereof | |
| CN105456815A (en) | Traditional Chinese medicine for inhibiting tumors and preparation method of traditional Chinese medicine | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN104689252A (en) | Traditional Chinese preparation for treating Wegener granulomatosis and preparation method thereof | |
| CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
| CN102688453A (en) | Traditional Chinese medicine composite for treating breast cancer | |
| CN101869629B (en) | Traditional Chinese medicine for treating renal calculus | |
| CN105688074A (en) | Decoction medicine for treating hypogastric pain and preparation method of decoction medicine | |
| CN105456954A (en) | Traditional Chinese medicine composition for treating acne and preparation thereof | |
| CN104825892A (en) | Traditional Chinese medicine preparation for treating ovulatory bleeding and preparation method of traditional Chinese medicine preparation | |
| CN105381410A (en) | Traditional Chinese medicinal preparation for treating hepatitis | |
| CN104740405A (en) | Traditional Chinese medicine preparation for treating anaphylactoid purpura renal damage and preparation method for traditional Chinese medicine preparation | |
| CN104888182A (en) | Traditional Chinese medicine preparation for treating postpartum abdominal pain and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160803 |